Artesunate study for infants with severe malaria
Treatments studied
Part of Infections clinical trials.
This trial studies how artesunate works in infants under 2 years old being treated for severe malaria. It aims to learn more about the medicine to help improve treatment for babies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is under 2 years old
- Your baby has been diagnosed with malaria (by a blood test or rapid test)
- Your baby has received at least one dose of artesunate through an IV (into a vein)
- Your baby does not have severe anemia (low red blood cells) when the extra blood sample is taken
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who were pregnant while receiving IV artesunate to better understand the treatment’s safety for both the mother and the baby. It does not test a new treatment—it collects safety information from real-world care.
This study tests a special dispersible tablet for infants with uncomplicated malaria. It aims to see if the medicine is safe and works well for babies weighing 2 to 5 kg.
This study aims to find the best way to treat or prevent malaria in children with HIV. It may also help children without HIV who live in areas where malaria is common.
This trial tests a combination of three malaria medicines in healthy volunteers to see how safe they are and how the body processes them. If you are a healthy non-smoker, you may be able to help researchers understand these drugs better.
This study looks at severe malaria in children from remote areas. It compares children with malaria, children with other severe fevers, and those with uncomplicated malaria to improve treatment in hard-to-reach villages.
This trial tests if artesunate, a malaria drug, is safe and tolerable for people with pulmonary arterial hypertension (PAH). It may offer a new treatment option for PAH patients whose symptoms persist despite using two or more standard therapies.
Hear when a new Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.